ReviewFrontiers in immunology2019
Tumors vs. Chronic Wounds: An Immune Cell's Perspective.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 74 citations in OpenAlex.
- The haunted Umwelt: a biosemiotic and hauntological account of immune semiotic corruption in field cancerization.Theory in biosciences = Theorie in den Biowissenschaften · 2026Article
- Tumor-Driven Inflammation Promotes Tumor Growth: A Focus on Anti-Inflammatory Cancer Treatments.Diseases (Basel, Switzerland) · 2026Review
- Shengji ointment accelerates diabetic foot ulcer wound healing by regulating inflammatory microenvironment.Frontiers in pharmacology · 2026Article
- Comorbidities' Effect on IPF: Pathogenesis and Management.Biomedicines · 2025Review
- One Step Ahead: Preventing Tumor Adaptation to Immune Therapy.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2025Review
- Multi-Omics Association Analysis of Mitochondrial Genes in Hypertrophic Scars: Application of Mendelian Randomization.Journal of inflammation research · 2025Article
- Air Pollution and Interstitial Lung Disease.Tuberculosis and respiratory diseases · 2025Article
- Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis.Journal of thoracic disease · 2024Article
- Targeting the tumour vasculature: from vessel destruction to promotion.Nature reviews. Cancer · 2024Review
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Schwann Cells as Orchestrators of Nerve Repair: Implications for Tissue Regeneration and Pathologies.Cold Spring Harbor perspectives in biology · 2024Review
- Neutrophil diversity is associated with T-cell immunity and clinical relevance in patients with thyroid cancer.Cell death discovery · 2024Article
- Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Communicator Extraordinaire: Extracellular Vesicles in the Tumor Microenvironment Are Essential Local and Long-Distance Mediators of Cancer Metastasis.Biomedicines · 2023Review
- Functionally Relevant Cytokine/Receptor Axes in Myelofibrosis.Biomedicines · 2023Review
- Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.Genes & diseases · 2023Review
- Clinical Implications of Immune Checkpoints and the RANK/RANK-L Signaling Pathway in High-Grade Canine Mast Cell Tumors.Animals : an open access journal from MDPI · 2023Article
- Mechanical High-Intensity Focused Ultrasound (Histotripsy) in Dogs With Spontaneously Occurring Soft Tissue Sarcomas.IEEE transactions on bio-medical engineering · 2023Article
- Tumor-associated macrophages-educated reparative macrophages promote diabetic wound healing.EMBO molecular medicine · 2023Article
- Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The wound repair program is tightly regulated and coordinated among different cell constituents including epithelial cells, fibroblasts, immune cells and endothelial cells following consecutive steps to ensure timely, and proper wound closure. Specifically, innate and adaptive immune cells are pivotal participants that also closely interact with the vasculature. Tumors are portrayed as wounds that do not heal because they undergo continuous stromal remodeling and vascular growth with immunosuppressive features to ensure tumor propagation; a stage that is reminiscent of the proliferative resolution phase in wound repair. There is increasing evidence from mouse model systems and clinical trials that targeting both the immune and vascular compartments is an attractive therapeutic approach to reawaken the inflammatory status in the "tumor wound" with the final goal to abrogate tumor cells and invigorate tissue homeostasis. In this review, we compare the implication of immune cells and the vasculature in chronic wounds and tumor wounds to underscore the conceptual idea of transitioning tumors into an inflammatory wound-like state with antiangiogenic immunotherapies to improve beneficial effects in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.